Dose Determination of Taxotere, Eloxatin and Xeloda (TEX) in Combination With Herceptin as First-line Treatment for Patients With HER2 Positive Non-resectable Oesophagus, Cardia or Gastric Cancer (ECV).
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2018
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Oxaliplatin (Primary) ; Trastuzumab (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Acronyms Her-TEX
- 04 Jan 2018 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Jan 2015).
- 19 Feb 2011 New trial record
- 14 Jan 2011 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database record.